BioSpace News Archive

BioVie Inc. today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID.

Bio-Path Holdings, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock, series A warrants to purchase up to 1,809,955 shares of common stock and short-term series B warrants to purchase up to 1,809,955 shares of common stock at a purchase price of $2.21 per share of common stock and accompanying warrants in a private placement priced at-the-market under Nasdaq rules.

Cue Biopharma today announced updated data from its ongoing Phase 1 trial evaluating its lead oncology asset from the CUE-100 series of biologics, CUE-101.

The Allen Institute for Cell Science unveiled a set of tools to accelerate research into hypertrophic cardiomyopathy, the most common genetic heart condition in the world: six new cell line collections, each carrying a different mutation associated with HCM.

Zeto, Inc., a privately owned medical technology company, has announced that its innovative next-generation product, named the ONE, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Leal Health (“Leal’’ or “the Company’’), a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that it will unveil new data on the benefits of digital health and AI-powered platforms for bridging cancer care gaps among diverse patient populations at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting.

Delix Therapeutics announced it has been awarded a $825,000 grant from the U.S. Department of Defense (DOD), to support the advancement of a neuroplastogen for hearing loss treatment.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program.

Seismic Therapeutic, Inc today announced that the company will participate in three upcoming scientific conferences.

Nalu Medical Inc. revealed significant findings from a landmark clinical trial evaluating the Nalu Peripheral Nerve Stimulation System utilizing their proprietary micro-implantable pulse generator to treat chronic pain patients.